WASHINGTON, DC, December 23, 2016 – Arlington Capital Partners (“Arlington Capital”), a Washington, DC-based private equity firm, today announced the acquisition of Molecular Products Group, Ltd. (“Molecular Products” or the “Company”). Headquartered in Harlow, Essex, U.K., Molecular Products is a leading manufacturer of advanced chemistry-based products serving the healthcare, defense and industrial markets. The Company primarily specializes in the manufacture and supply of chemical technologies for the treatment of breathable gases and is able to serve its global customer base out of its two primary manufacturing facilities in Harlow, Essex, U.K. and Boulder, CO.
Peter Manos, a Managing Partner at Arlington Capital, said “We are excited to be partnering with CEO Troy Rhudy and his management team at Molecular Products to expand the Company’s unique position in the development of advanced chemistry-based applications for the healthcare and defense markets, which are key verticals for Arlington. Molecular Products continues Arlington’s long track record of investing in industry leading companies with technically differentiated and proven products in the market.”
Troy Rhudy, CEO of Molecular Products, stated, “Arlington Capital and Molecular Products have a shared vision to build upon the Company’s reputation as a world-class specialty chemical manufacturing Company and we are looking forward to a period of transformational growth both through strategic acquisitions and organic growth.”
Chris Stallmann, a Vice President at Arlington Capital, said, “We look forward to supporting the Company’s continued expansion of their specialty chemical manufacturing capabilities and bringing to market its robust pipeline of technologically differentiated and innovative next generation air purification products.”
About Molecular Products
Molecular Products specializes in the manufacture and distribution of chemical technology for the purification of air to preserve life and protect the environment. Founded in 1924, it is a global leader in its field, offering a complete product solution for the removal of carbon dioxide, the generation of oxygen and filtration of hazardous or harmful emissions. Molecular Products has over 130 employees with manufacturing operations in Harlow, Essex, U.K. and Boulder CO, and distribution offices in Australia, China and India.
About Arlington Capital Partners
Arlington Capital Partners is a Washington, D.C.-area private equity firm that has managed $2.2 billion of committed capital via four investment funds, including Arlington’s fourth and most recent $700 million fund. Arlington is focused on middle market investment opportunities in growth industries including: aerospace/defense, healthcare, government services and technology and business services and software. The firm’s professionals and network have a unique combination of operating and private equity experience that enables Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their company’s position as leading competitors in their field. www.arlingtoncap.com
Peter Manos or Chris Stallmann
Arlington Capital Partners
5425 Wisconsin Avenue, Suite 200
Chevy Chase, MD 20815
(202) 337-7525 (fax)